A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

NCT01876771 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Neuroendocrine

Interventions

DRUG: [177]Lu-DOTA-TATE

Sponsor

AHS Cancer Control Alberta